肠道微生物群——癌症免疫治疗的双刃剑。
Gut microbiota - a double-edged sword in cancer immunotherapy.
机构信息
Department of Medicine - Alfred, Monash University, Melbourne, Victoria, Australia.
Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia; La Trobe University, Bundoora, Victoria, Australia.
出版信息
Trends Cancer. 2023 Jan;9(1):3-5. doi: 10.1016/j.trecan.2022.08.003. Epub 2022 Sep 8.
Immune checkpoint blockade (ICB) has revolutionized cancer treatment. However, many patients fail to respond to this therapy or experience side effects. Recently, gut microbiota have emerged as a key determinant of ICB efficacy and toxicity, making manipulation of the microbiome a novel therapeutic strategy with which to improve ICB outcomes.
免疫检查点阻断（ICB）已经彻底改变了癌症治疗。然而，许多患者对这种治疗方法没有反应或出现副作用。最近，肠道微生物群已成为 ICB 疗效和毒性的关键决定因素，这使得对微生物组的操纵成为一种改善 ICB 结果的新的治疗策略。
Zotero 插件